UnitedHealth Group (NYSE:UNH) Coverage Initiated by Analysts at The Goldman Sachs Group

Key Points

• Analysts at The Goldman Sachs Group initiated coverage on UnitedHealth Group, providing a "buy" rating and setting a price target of $406.00, indicating a potential upside of 13.15% from its previous close.
• Despite the positive outlook from Goldman Sachs, other analysts have mixed ratings, with Weiss Ratings giving it a "sell (d+)" and a consensus rating of "Hold" across 28 analysts that includes 17 buy ratings.
• UnitedHealth Group's recent quarterly earnings report showed earnings per share of $4.08, which fell short of estimates, although the company achieved a revenue increase of 12.9% year-over-year.

Stock analysts at The Goldman Sachs Group started coverage on shares of UnitedHealth Group (NYSE:UNH - Get Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The firm set a "buy" rating and a $406.00 price target on the healthcare conglomerate's stock. The Goldman Sachs Group's price target points to a potential upside of 13.15% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of UnitedHealth Group in a research report on Wednesday, October 8th. Truist Financial upped their price target on shares of UnitedHealth Group from $310.00 to $365.00 and gave the stock a "buy" rating in a report on Tuesday, September 9th. Morgan Stanley boosted their price objective on shares of UnitedHealth Group from $325.00 to $395.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. UBS Group reaffirmed a "buy" rating on shares of UnitedHealth Group in a research report on Thursday, July 17th. Finally, Oppenheimer cut their price objective on shares of UnitedHealth Group from $400.00 to $325.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 30th. Seventeen analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $384.09.

UnitedHealth Group Trading Up 1.2%

Shares of NYSE:UNH opened at $358.80 on Tuesday. UnitedHealth Group has a 12-month low of $234.60 and a 12-month high of $630.73. The stock has a market cap of $324.96 billion, a PE ratio of 15.55, a P/E/G ratio of 2.29 and a beta of 0.47. The business has a 50 day moving average of $320.57 and a 200-day moving average of $346.99. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The firm had revenue of $111.62 billion for the quarter, compared to the consensus estimate of $111.75 billion. During the same quarter in the prior year, the firm earned $6.80 EPS. The company's revenue was up 12.9% on a year-over-year basis. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. As a group, equities research analysts forecast that UnitedHealth Group will post 29.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Generali Investments CEE investicni spolecnost a.s. boosted its holdings in UnitedHealth Group by 1.9% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 13,098 shares of the healthcare conglomerate's stock worth $4,523,000 after buying an additional 238 shares during the period. First Bank & Trust boosted its holdings in UnitedHealth Group by 39.8% in the 3rd quarter. First Bank & Trust now owns 1,892 shares of the healthcare conglomerate's stock valued at $653,000 after purchasing an additional 539 shares during the period. Spinnaker Investment Group LLC boosted its holdings in UnitedHealth Group by 217.0% in the 3rd quarter. Spinnaker Investment Group LLC now owns 2,232 shares of the healthcare conglomerate's stock valued at $771,000 after purchasing an additional 1,528 shares during the period. Lineweaver Wealth Advisors LLC boosted its holdings in UnitedHealth Group by 3.8% in the 3rd quarter. Lineweaver Wealth Advisors LLC now owns 6,340 shares of the healthcare conglomerate's stock valued at $2,189,000 after purchasing an additional 231 shares during the period. Finally, Tlwm boosted its holdings in UnitedHealth Group by 5.9% in the 3rd quarter. Tlwm now owns 2,836 shares of the healthcare conglomerate's stock valued at $979,000 after purchasing an additional 159 shares during the period. 87.86% of the stock is owned by institutional investors.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.